76 results
8-K
EX-99.1
BFRI
Biofrontera Inc
15 Mar 24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
5:20pm
study of safety and efficacy of Ameluz® and RhodoLED® XL for treatment of AK on the extremities, neck and trunk.
“I am pleased to announce 2023
8-K
EX-10.1
po2joxa
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-10.2
k1xq1n
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
rwb5cs6lvvnypzwv4a1s
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use
5:25pm
8-K
EX-99.1
pgm7 vxyejjhlncu8
9 Nov 23
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
5:15pm
8-K
EX-10.2
qymh4cvi7jbqsbhn 07w
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-10.1
m9iu4
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
vmkq8 w7m
1 Nov 23
Prospectus supplement with pricing info
5:09pm